Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction

Journal of Cachexia, Sarcopenia and Muscle

Volumn , Issue , 2015, Pages 32-44

  Faber, Joyce ^a,b   Uitdehaag, Madeleen J ^c   Spaander, Manon ^c   van Steenbergen Langeveld, Sabine ^d   Vos, Paul ^a,b   Berkhout, Marloes ^a   Lamers, Cor ^d   Rümke, Hans ^e   Tilanus, Hugo ^c   Siersema, Peter ^c,f   van Helvoort, Ardy ^a   van der Gaast, Ate ^c  

^a DANONE NUTRICIA RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e University Vaccine Center Rotterdam Nijmegen   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Body weight; Cancer; Clinical; Medical food; Nutrition; PGE2

Indexed keywords

FISH OIL; LEUCINE; OLIGOSACCHARIDE; PLACEBO; PROSTAGLANDIN E2; PROTEIN;

ADULT; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ELECTROCORTICOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; EX VIVO STUDY; FEMALE; GASTROESOPHAGEAL JUNCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NUTRITION; NUTRITIONAL STATUS; PERFORMANCE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

EID: 84982083987     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12009     Document Type: Article

References (52)

1. Barber MD, Ross JA, Fearon KC. Cancer cachexia. Surg Oncol 1999;8:133–141.
2. Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 2000;34:137–168.
3. Van Bokhorst-de Van der Schueren MA. Nutritional support strategies for malnourished cancer patients. Eur J Oncol Nurs 2005;9:S74–S83.
4. Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs 2005;9:S39–S50.
5. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Jr., Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491–497.
6. Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005;9:S51–S63.
7. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006;42:31–41.
8. Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006;24:1163–1177.
9. Ross JA, Fearon KC. Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 2002;5:241–248.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–867.
11. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–444.
12. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006;16:38–52.
13. Young MR. Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 1994;13:337–348.
14. Laviano A, Meguid MM. Nutritional issues in cancer management. Nutrition 1996;12:358–371.
15. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 2003;3:1061–1071.
16. Herber DL, Nagaraj S, Djeu JY, Gabrilovich DI. Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res 2007;67:5067–5069.
17. Kotler DP. Cachexia. Ann Intern Med 2000;133:622–634.
18. Senesse P, Assenat E, Schneider S, Chargari C, Magne N, Azria D, Hebuterne X. Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit? Cancer Treat Rev 2008;34:568–575.
19. Muscaritoli M, Costelli P, Aversa Z, Bonetto A, Baccino FM, Rossi Fanelli F. New strategies to overcome cancer cachexia: from molecular mechanisms to the 'parallel pathway'. Asia Pac J Clin Nutr 2008;17:387–390.
20. Faber J, Vos AP, Kegler D, Argiles J, Laviano A, Garssen J, van Helvoort A. Impaired immune function: an early marker for cancer cachexia. Oncol Rep 2009;22:1403–1406.
21. Faber J, Vos P, Kegler D, van Norren K, Argiles JM, Laviano A, Garssen J, van Helvoort A. Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia. Br J Cancer 2008;99:2029–2036.
22. van Norren K, Kegler D, Argiles JM, Luiking Y, Gorselink M, Laviano A, Arts K, Faber J, Jansen H, van der Beek EM, van Helvoort A. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 2009;100:713–722.
23. US Food and Drug Administration. Frequently Asked Questions About Medical Foods. In: College Park MF, Center for Food Safety and Applied Nutrition, US Department of Health and Human Services, editor. 2007.
24. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457–1459.
25. Albers R, Antoine JM, Bourdet-Sicard R, Calder PC, Gleeson M, Lesourd B, Samartin S, Sanderson IR, Van Loo J, Vas Dias FW, Watzl B. Markers to measure immunomodulation in human nutrition intervention studies. Br J Nutr 2005;94:452–481.
26. Lamers HJ, Gratama JW, van Putten WL, Stoter G, Bolhuis RL. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Cancer Res 1991;51:2324–2328.
27. Lamers CH, Gratama JW, Pouw NM, Langeveld SC, Krimpen BA, Kraan J, Stoter G, Debets R. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression. Hum Gene Ther 2005;16:1452–1462.
28. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
29. Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 1993;329:1302–1307.
30. Takagi K, Yamamori H, Furukawa K, Miyazaki M, Tashiro T. Perioperative supplementation of EPA reduces immunosuppression induced by postoperative chemoradiation therapy in patients with esophageal cancer. Nutrition 2001;17:478–479.
31. Furukawa K, Tashiro T, Yamamori H, Takagi K, Morishima Y, Sugiura T, Otsubo Y, Hayashi N, Itabashi T, Sano W, Toyoda Y, Nitta H, Nakajima N. Effects of soybean oil emulsion and eicosapentaenoic acid on stress response and immune function after a severely stressful operation, Ann Surg 1999;229:255–261.
32. Sephton SE, Kraemer HC, Neri E, Stites DP, Weissbecker I, Spiegel D. Improving methods of assessing natural killer cell cytotoxicity. Int J Methods Psychiatr Res 2006;15:12–21.
33. Deutz NE, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, van Helvoort A, Wolfe RR. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr 2011.
34. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223–226.
35. Smith KL, Tisdale MJ. Mechanism of muscle protein degradation in cancer cachexia. Br J Cancer 1993;68:314–318.
36. Serafini P. Editorial: PGE2-producing MDSC: a role in tumor progression? J Leukoc Biol 2010;88:827–829.
37. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181–193.
38. Rodriguez-Vita J, Lawrence T. The resolution of inflammation and cancer. Cytokine Growth Factor Rev 2010;21:61–65.
39. Shaikh SR, Edidin M. Polyunsaturated fatty acids and membrane organization: elucidating mechanisms to balance immunotherapy and susceptibility to infection. Chem Phys Lipids 2008;153:24–33.
40. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499–4506.
41. Zuijdgeest-van Leeuwen SD, van der Heijden MS, Rietveld T, van den Berg JW, Tilanus HW, Burgers JA, Wilson JH, Dagnelie PC. Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects. Clin Nutr 2002;21:225–230.
42. Murphy RA, Bureyko TF, Mourtzakis M, Chu QS, Clandinin MT, Reiman T, Mazurak VC. Aberrations in plasma phospholipid fatty acids in lung cancer patients. Lipids 2012;47:363–369.
43. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr 2010;140:1602–1606.
44. Calder PC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S–1519S.
45. Wu D, Meydani SN. N-3 polyunsaturated fatty acids and immune function. Proc Nutr Soc 1998;57:503–509.
46. Faber J, Berkhout M, Vos AP, Sijben JW, Calder PC, Garssen J, van Helvoort A. Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. J Nutr 2011;141:964–970.
47. Lomax AR, Calder PC. Prebiotics, immune function, infection and inflammation: a review of the evidence. Br J Nutr 2009;101:633–658.
48. Vos A, M'Rabet L, Stahl B, Boehm G, Garssen J. Immune-modulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 2007;27:97–140.
49. Saito T, Kuwahara A, Shigemitsu Y, Kinoshita T, Shimoda K, Miyahara M, Kobayashi M, Shimaoka A. Factors related to malnutrition in patients with esophageal cancer. Nutrition 1991;7:117–121.
50. Tashiro T, Yamamori H, Takagi K, Hayashi N, Furukawa K, Nitta H, Toyoda Y, Sano W, Itabashi T, Nishima K, Hirano J, Nakajima N. Changes in immune function following surgery for esophageal carcinoma. Nutrition 1999;15:760–766.
51. Hori H, Kawano T, Endo M, Yuasa Y. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J Clin Gastroenterol 1997;25:568–575.
52. Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 1999;48:435–442.